Plus, news about Phathom and CANbridge:
Avidity Biosciences closes $345.1M offering: The raise comes on the heels of Phase 1/2 data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.